期刊文献+

胰高血糖素样肽1受体激动剂对血糖波动和氧化应激的影响 被引量:2

Effect of glucagon like peptide 1 receptor agonist on blood glucose fluctuation and oxidative stress
原文传递
导出
摘要 氧化应激通过影响多种信号传导通路,诱导炎症反应,促进组织、细胞损伤和凋亡,参与糖尿病及其并发症的发生发展。血糖波动可加剧氧化应激,加重组织损伤凋亡。胰高血糖素样肽-1( GLP-1)受体激动剂特异性的与其受体结合,发挥多系统生理效应,延缓胃排空、降低食欲、减少食物摄入量及减轻体质量,增强葡萄糖依赖性的胰岛素分泌、抑制葡萄糖依赖性的胰高血糖素分泌,改善血糖波动。另外,GLP-1通过自身调控功能,降低活性氧簇,抑制氧化酶活性,上调抗氧化防御相关基因,增加抗氧化酶水平,减轻氧化应激状态。 Objective Oxidative stress which participates in the development of diabetes and its complications can induce inflammation and increase the damage and apoptosis on cells and tissue by influencing multiple signaling pathways-Blood glucose fluctuation increased oxidative stress and aggravated damage and apoptosis on cells.The roles of glucagon-like peptide-1 ( GLP-1) receptor agonist can improve blood glucose fluctuation by playing multiple system physiological effects,such as,delaying gastric emptying,reducing appetite, food intake and body weight, enhancing glucose dependent insulin secretion, inhibiting glucose dependent glucagon secretion-In addition,GLP-1 can reduce oxidative stress state by reducing the reactive oxygen species, inhibiting oxidase activity,up-regulating anti-oxidative stress genes,increasing the level of antioxidant enzymes.
作者 薛慧 李强
出处 《中国综合临床》 2016年第8期746-749,共4页 Clinical Medicine of China
基金 国家自然科学基金(81170744,81370902)
关键词 胰高血糖素样肽1受体激动剂 血糖 氧化应激 Glucagon-like peptide-1 Blood glucose fluctuation Oxidative stress
  • 相关文献

参考文献2

二级参考文献10

  • 1周健,喻明,贾伟平,李青,李鸣,马晓静,陆蔚,项坤三.应用动态血糖监测系统评估2型糖尿病患者日内及日间血糖波动幅度[J].中华内分泌代谢杂志,2006,22(3):286-288. 被引量:177
  • 2Russell-Jones D,Vaag A,Schmitz O,et al.Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus(LEAD-5 met+ SU):a randomised controlled trial[J].Diabetologia,2009,52:2046-2055.
  • 3Zinman B,Gerich J,Buse JB,et al.Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes(LEAD-4 Met+TZD)[J].Diabetes Care,2009,32:1224-1230.
  • 4Unger J.Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm[J].J Am Osteopath Assoc,2011,111:2-9.
  • 5Mori Y,Taniguchi Y,Sezaki K,et al.Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drugnaive type 2 diabetes patients:a continuous glucose monitoringbased study[J].Diabetes Technol Ther,2011,13:1139-1144.
  • 6Russell-Jones D.Molecular,pharmacological and clinical aspects of liraglutide,a once-daily human GLP-1 analogue[J].Mol Cell Endocrinol,2009,297:137-140.
  • 7Garber A,Henry R,Ratner R,et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD-3 Mono):a randomised,52-week,phase Ⅲ,double-blind,parallel-treatment trial[J].Lancet,2009,373:473-481.
  • 8王丽,陈庆伟,李桂琼,柯大智.生长激素促分泌物受体的内源性配体ghrelin促进大鼠心肌微血管内皮细胞体外血管生成[J].中华心血管病杂志,2012,40(1):50-56. 被引量:10
  • 9周健,贾伟平.实时动态血糖监测:准确把握与规范应用[J].中华糖尿病杂志,2013,5(1):4-6. 被引量:15
  • 10陆菊明.利拉鲁肽早期和长期应用为2型糖尿病综合管理带来益处[J].中华内分泌代谢杂志,2013,29(5). 被引量:2

共引文献14

同被引文献23

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部